EMAIL THIS PAGE TO A FRIEND

Cardiovascular therapeutics

Fenoldopam in critically ill patients with early renal dysfunction. A crossover study.


PMID 20955210

Abstract

Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an option to prevent further damage. We performed a randomized, double-blinded, prospective crossover study in 17 patients admitted to our trauma intensive care unit (ICU) with evidence of impaired renal function. Patients were randomized to a 24-h intravenous infusion of low-dose fenoldopam or placebo. When the infusion of fenoldopam or placebo was completed, patients underwent a 24-h "washout" period in which no study intervention was performed. This sequence was repeated in each patient with the opposite agent, so each patient served as his own control. Four-hour creatinine collections were taken during the last 4 h of each infusion and washout periods to determine creatinine clearance changes during and after the administration of the study drug. The creatinine clearance was higher with fenoldopam infusion than with placebo infusion (P = 0.045). The FENa was not significantly different. Our study showed that low-dose Fenoldopam increases creatinine clearance in the critically ill with renal insufficiency. Fenoldopam may be a useful drug in ICU patients with early renal dysfunction.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SML0198
Fenoldopam mesylate, ≥98% (HPLC)
C16H16ClNO3 · CH4O3S
F6800
Fenoldopam monohydrobromide, ≥98%
C16H16ClNO3 · HBr